 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...979899100101102103104105106107...132133» |
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck (clinicaltrials.gov) - May 16, 2017
P2, N=80, Active, not recruiting, Sponsor: University of Chicago
Trial primary completion date: Apr 2017 --> Sep 2017
- | Zejula (niraparib) / GSK, J&J, Takeda
New P1 trial, Combination therapy, Metastases: Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast (clinicaltrials.gov) - May 15, 2017
P1, N=24, Not yet recruiting, Sponsor: Avera McKennan Hospital & University Health Center
- | everolimus / Generic mfg.
Enrollment open: RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome (clinicaltrials.gov) - May 15, 2017
P1/2, N=40, Recruiting, Sponsor: Boston Children’s Hospital
Trial primary completion date: Apr 2017 --> Sep 2017 Not yet recruiting --> Recruiting
- |||| everolimus / Generic mfg.
Enrollment open, Enrollment change, Trial primary completion date, Metastases: Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China (clinicaltrials.gov) - May 15, 2017
P4, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | N=31 --> 60 | Trial primary completion date: Mar 2020 --> Sep 2023
- || serabelisib (MLN1117) / Takeda
Trial primary completion date, Metastases: MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma (clinicaltrials.gov) - May 12, 2017
P2, N=189, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Recruiting | N=31 --> 60 | Trial primary completion date: Mar 2020 --> Sep 2023 Trial primary completion date: May 2017 --> Mar 2018
- | Mycobutin (rifabutin) / Pfizer, Lupin
Biomarker, Enrollment open: TBHDT: TB Host Directed Therapy (clinicaltrials.gov) - May 12, 2017
P2, N=200, Recruiting, Sponsor: The Aurum Institute NPC
Trial primary completion date: May 2017 --> Mar 2018 Not yet recruiting --> Recruiting
- | everolimus / Generic mfg.
Trial primary completion date, Combination therapy: Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - May 11, 2017
P1/2, N=125, Recruiting, Sponsor: University of Cologne
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2016 --> Aug 2017
- everolimus / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date: RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder (clinicaltrials.gov) - May 11, 2017
P1/2, N=33, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Aug 2016 --> Aug 2017 Trial primary completion date: Dec 2017 --> Dec 2018
- || everolimus / Generic mfg., sirolimus / Generic mfg.
Trial primary completion date, Adverse events, Combination therapy: Comparing Everolimus and Sirolimus in Renal Transplant Recipients (clinicaltrials.gov) - May 11, 2017
P=N/A, N=60, Active, not recruiting, Sponsor: Dr.Ronald Pelletier
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Feb 2017 --> May 2018
- |||| everolimus / Generic mfg.
Enrollment open, Trial primary completion date: PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children (clinicaltrials.gov) - May 10, 2017
P2, N=65, Recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Feb 2017 --> May 2018 Active, not recruiting --> Recruiting | Trial primary completion date: Mar 2017 --> Mar 2019
- | everolimus / Generic mfg.
Enrollment closed, Trial primary completion date, Metastases: Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors (clinicaltrials.gov) - May 10, 2017
P2, N=25, Active, not recruiting, Sponsor: Hellenic Cooperative Oncology Group
Active, not recruiting --> Recruiting | Trial primary completion date: Mar 2017 --> Mar 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Jan 2017
- |||| cyclophosphamide / Generic mfg., everolimus / Generic mfg.
Trial completion, Metastases: Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer (clinicaltrials.gov) - May 10, 2017
P1/2, N=96, Completed, Sponsor: Hans J. van der Vliet, MD, PhD
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Jan 2017 Recruiting --> Completed
- | ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion, Trial primary completion date, Combination therapy, Metastases: Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 10, 2017
P1, N=27, Completed, Sponsor: Shadia Jalal
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2020 --> Jan 2015
- prednisone / Generic mfg., everolimus / Generic mfg.
Trial primary completion date: PredEver first: Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus (clinicaltrials.gov) - May 9, 2017
P2a, N=38, Active, not recruiting, Sponsor: Universitätsklinikum Hamburg-Eppendorf
Active, not recruiting --> Completed | Trial primary completion date: May 2020 --> Jan 2015 Trial primary completion date: Jan 2017 --> Jan 2018
- | everolimus / Generic mfg.
Trial primary completion date: A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD (clinicaltrials.gov) - May 8, 2017
P2, N=30, Recruiting, Sponsor: New York University School of Medicine
Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Mar 2017 --> Jun 2018
- everolimus / Generic mfg.
Trial primary completion date: EXIST-LT: Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus (clinicaltrials.gov) - May 8, 2017
P4, N=15, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2017 --> Jun 2018 Trial primary completion date: Feb 2026 --> Sep 2026
- | everolimus / Generic mfg.
Trial primary completion date: SAKK 08/08: Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - May 4, 2017
P2, N=37, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Trial primary completion date: Feb 2026 --> Sep 2026 Trial primary completion date: Aug 2010 --> Nov 2012
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone (clinicaltrials.gov) - May 4, 2017
P2, N=40, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- | everolimus / Generic mfg.
Trial termination: Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC (clinicaltrials.gov) - May 3, 2017
P2, N=65, Terminated, Sponsor: Novartis Pharmaceuticals
Completed --> Terminated; The study was terminated due to low enrollment. This resulted in the study being underpowered and inconclusive.
- || Trial primary completion date, Metastases: SAFIR-TOR: Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor (clinicaltrials.gov) - May 3, 2017
P=N/A, N=150, Recruiting, Sponsor: UNICANCER
This resulted in the study being underpowered and inconclusive. Trial primary completion date: Jul 2017 --> Jan 2018
- || Trial primary completion date, Combination therapy, Metastases: Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - May 2, 2017
P4, N=70, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2017 --> Jan 2018 Trial primary completion date: Dec 2016 --> Jul 2017
- | Trial primary completion date: A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys (clinicaltrials.gov) - Apr 27, 2017
P2/3, N=50, Recruiting, Sponsor: Matthew Cooper
Trial primary completion date: Dec 2016 --> Jul 2017 Trial primary completion date: Mar 2017 --> Nov 2017
- | Trial primary completion date, Surgery, Metastases: Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus (clinicaltrials.gov) - Apr 26, 2017
P2, N=66, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial primary completion date: Mar 2017 --> Nov 2017 Trial primary completion date: Feb 2017 --> Feb 2018
- | everolimus / Generic mfg.
Trial initiation date, Trial primary completion date, Monotherapy: Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma (clinicaltrials.gov) - Apr 26, 2017
P2, N=25, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial primary completion date: Feb 2017 --> Feb 2018 Initiation date: Dec 2012 --> Jul 2015 | Trial primary completion date: Feb 2017 --> Feb 2018
- | Kisqali (ribociclib) / Novartis
Trial initiation date, Trial primary completion date, Metastases: LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy (clinicaltrials.gov) - Apr 25, 2017
P1/2, N=44, Not yet recruiting, Sponsor: Georgetown University
Initiation date: Dec 2012 --> Jul 2015 | Trial primary completion date: Feb 2017 --> Feb 2018 Initiation date: Dec 2016 --> May 2017 | Trial primary completion date: Dec 2019 --> Dec 2020
- Odomzo (sonidegib) / Sun Pharma
Enrollment closed, Enrollment change, Combination therapy, Metastases: LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Apr 24, 2017
P1, N=25, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Dec 2016 --> May 2017 | Trial primary completion date: Dec 2019 --> Dec 2020 Recruiting --> Active, not recruiting | N=42 --> 25
- | Avastin (bevacizumab) / Roche
Journal: Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. (Pubmed Central) - Apr 22, 2017
Objective response was limited to patients with PI3K pathway aberration. A randomized trial should be performed to test DAT and DAE for metaplastic TNBC, as well as nonmetaplastic, mesenchymal TNBC, especially when PI3K pathway aberrations are identified.
- ||||||| everolimus / Generic mfg.
Trial completion, Combination therapy: 4EVERLUNG: Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients (clinicaltrials.gov) - Apr 21, 2017
P3, N=131, Completed, Sponsor: Novartis Pharmaceuticals
A randomized trial should be performed to test DAT and DAE for metaplastic TNBC, as well as nonmetaplastic, mesenchymal TNBC, especially when PI3K pathway aberrations are identified. Active, not recruiting --> Completed
- |||| everolimus / Generic mfg., exemestane / Generic mfg.
Trial completion, Combination therapy, Metastases: 4EVER UK: An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis (clinicaltrials.gov) - Apr 21, 2017
P4, N=52, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | sapanisertib (CB-228) / Calithera
Phase classification, Combination therapy, Metastases: Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer (clinicaltrials.gov) - Apr 21, 2017
P1b/2, N=126, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed Phase classification: P1/2 --> P1b/2
- everolimus / Generic mfg.
Trial primary completion date: INPRES: Influence of Exceptional Patient Characteristics on Everolimus Exposure (clinicaltrials.gov) - Apr 20, 2017
P4, N=50, Recruiting, Sponsor: Radboud University
Phase classification: P1/2 --> P1b/2 Trial primary completion date: Dec 2016 --> Jun 2017
- | everolimus / Generic mfg.
Trial primary completion date: Prediction of Everolimus-induced Interstitial Lung Disease (clinicaltrials.gov) - Apr 20, 2017
P=N/A, N=25, Recruiting, Sponsor: Radboud University
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Dec 2016 --> Jun 2017
- || carboplatin / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer (clinicaltrials.gov) - Apr 20, 2017
P2, N=72, Recruiting, Sponsor: Amy Tiersten
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Feb 2017 --> Jun 2018
- |||| davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial completion, Trial primary completion date, Combination therapy, Metastases: CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) (clinicaltrials.gov) - Apr 20, 2017
P2, N=115, Completed, Sponsor: NewLink Genetics Corporation
Trial primary completion date: Feb 2017 --> Jun 2018 Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2016
- everolimus / Generic mfg.
Trial primary completion date: Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer (clinicaltrials.gov) - Apr 17, 2017
P2, N=42, Active, not recruiting, Sponsor: Emory University
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2016 Trial primary completion date: Apr 2017 --> Apr 2018
- | Kisqali (ribociclib) / Novartis
New P2 trial, Combination therapy, Metastases: Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) (clinicaltrials.gov) - Apr 13, 2017
P2, N=48, Not yet recruiting, Sponsor: Fox Chase Cancer Center
- |||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion, Trial primary completion date, Metastases: RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 13, 2017
P1/2, N=56, Completed, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Apr 2017 --> Apr 2018 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2013
- |||||||||| Jakafi (ruxolitinib) / Novartis, Incyte
New P3 trial: A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) (clinicaltrials.gov) - Apr 13, 2017
P3, N=324, Not yet recruiting, Sponsor: Incyte Corporation
- | Avastin (bevacizumab) / Roche
Trial completion, Trial initiation date, Trial primary completion date, Metastases: Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer (clinicaltrials.gov) - Apr 11, 2017
P1/2, N=27, Completed, Sponsor: University of Southern California
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2013 Active, not recruiting --> Completed | Initiation date: Sep 2007 --> Feb 2010 | Trial primary completion date: Aug 2016 --> Feb 2016
- | Votrient (pazopanib) / Novartis, sunitinib / Generic mfg., Zelboraf (vemurafenib) / Roche
Enrollment closed, Trial primary completion date, Metastases: ICK: Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=43, Active, not recruiting, Sponsor: VU University Medical Center
Active, not recruiting --> Completed | Initiation date: Sep 2007 --> Feb 2010 | Trial primary completion date: Aug 2016 --> Feb 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2017
- || Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date, Combination therapy, Metastases: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Apr 7, 2017
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2017 Trial primary completion date: May 2017 --> Dec 2018
- | Sutent (sunitinib) / Pfizer
Enrollment change, Trial termination, Trial primary completion date, IO biomarker: Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=8, Terminated, Sponsor: VU University Medical Center
Trial primary completion date: May 2017 --> Dec 2018 N=120 --> 8 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Apr 2017
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma (clinicaltrials.gov) - Apr 4, 2017
P2, N=149, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=120 --> 8 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Apr 2017 Active, not recruiting --> Completed
- | everolimus / Generic mfg.
Enrollment change, Metastases: Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations (clinicaltrials.gov) - Apr 4, 2017
P2, N=12, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed N=10 --> 12
- | letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date: A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Apr 4, 2017
P2, N=40, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
N=10 --> 12 Trial primary completion date: Jul 2018 --> Jul 2019
- | everolimus / Generic mfg., sirolimus / Generic mfg., itraconazole / Generic mfg.
Trial primary completion date: Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics (clinicaltrials.gov) - Mar 31, 2017
P=N/A, N=126, Recruiting, Sponsor: Radboud University
Trial primary completion date: Jul 2018 --> Jul 2019 Trial primary completion date: Dec 2016 --> Dec 2017
- || Enrollment closed, Trial primary completion date, IO biomarker, Metastases: Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane (clinicaltrials.gov) - Mar 31, 2017
P=N/A, N=175, Active, not recruiting, Sponsor: VU University Medical Center
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Sep 2017
- | Envarsus (LCP-Tacro) / Asahi Kasei
Enrollment open, Combination therapy: Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study (clinicaltrials.gov) - Mar 30, 2017
P2, N=25, Recruiting, Sponsor: Chiesi Farmaceutici S.p.A.
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Sep 2017 Not yet recruiting --> Recruiting
- Farydak (panobinostat) / Secura Bio
Trial initiation date, Combination therapy, Epigenetic controller: Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors (clinicaltrials.gov) - Mar 30, 2017
P1, N=49, Active, not recruiting, Sponsor: National Cancer Centre, Singapore
Not yet recruiting --> Recruiting Initiation date: Jan 2011 --> Mar 2010
- | cisplatin / Generic mfg., everolimus / Generic mfg., gemcitabine / Generic mfg.
Phase classification, Enrollment change, Trial termination, Metastases: Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer (clinicaltrials.gov) - Mar 30, 2017
P1/2, N=23, Terminated, Sponsor: National Cancer Center, Korea
Initiation date: Jan 2011 --> Mar 2010 Phase classification: P2 --> P1/2 | N=116 --> 23 | Active, not recruiting --> Terminated; slow recruitment